Pregnant

Developed for the Puerto Rico Department of Health, this toolkit discusses how to screen pregnant women for substance use, screen infants for prenatal exposure to substances, recognize the signs of NAS, utilize validated screening tools, understand the importance of provider education, and engage pregnant women in the process of treatment and referral.

Medications for opioid use disorder, including buprenorphine hydrochloride and methadone hydrochloride, are highly effective at improving outcomes for individuals with the disorder. For pregnant women, use of these medications also improves pregnancy outcomes, including the risk of preterm birth. Despite the known benefits of medications for opioid use disorder, many pregnant and nonpregnant women with the disorder are not receiving them.

Prescription opioid use during pregnancy has been associated with poor outcomes for mothers and infants. Studies using administrative data have estimated that 14%–22% of women filled a prescription for opioids during pregnancy; however, data on self-reported prescription opioid use during pregnancy are limited.

The Opioid Use Disorder, Pregnant Women and Neonatal Abstinence Syndrome (NAS): Addressing the Challenges (Part II) webinar took place on June 9, 2020.

Mother & Baby Substance Exposure Toolkit Best Practices All Best Practices came as a part of the California Medication Assisted Treatment Expansion Project

Stigma keeps people from the best possible care. Beyond Labels is a free Anti-Stigma Toolkit for Women & Babies toolkit from the March of Dimes and RTI International.

The CHARM or “CHildren And Recovering Mothers” Collaborative is a group of providers from in and around Waldo County, Maine, who are serving mothers and families dealing with pregnancy that is affected by substance use.